Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ESREW
ADC Name
IGF-MTX
Synonyms
IGFMTX; IGF MTX; IGF-drug conjugates(IGF Oncology LLC); IGF-drug conjugates
   Click to Show/Hide
Organization
IGF Oncology LLC
Drug Status
Phase 1/2
Indication
In total 1 Indication(s)
Myelodysplastic syndrome [ICD11:2A37]
Phase 1/2
Antibody Name
Anti-IGF1R mAb
  Antibody Info 
Antigen Name
Insulin-like growth factor 1 receptor (IGF1R)
  Antigen Info 
Payload Name
Methotrexate
  Payload Info 
Therapeutic Target
Dihydrofolate reductase (DHFR)
  Target Info 
Linker Name
Undisclosed
TTD ID
D0P3ZF
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 98.34
%
Undisclosed Undisclosed
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 98.34%
References
Ref 1 IGF Oncology biotechnology company product pipeline

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.